Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Aug 7 · above the Ichimoku cloud · RSI 63 · MACD above its signal · 2% below its 52-week high
None of the 29 investors followed here reported a position in CBLL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CBLL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Chao XingjuanChief Executive Officer | Sale at price 25.03 per share. | 20.8K | $521.77K |
| Sep 14, 2026 | Blumberg ScottChief Financial Officer | Sale at price 25.00 per share. | 846 | $21.15K |
| Sep 14, 2026 | Blumberg ScottChief Financial Officer | Conversion of Exercise of derivative security at price 9.41 per share. | 846 | $7.96K |
| Sep 7, 2026 | Woo RaymondChief Technology Officer | Sale at price 24.33 per share. | 4.9K | $118.90K |
| Sep 7, 2026 | Woo RaymondChief Technology Officer | Conversion of Exercise of derivative security at price 2.24 - 4.70 per share. | 13.3K | $36.65K |
| Sep 7, 2026 | Foehr DavidOfficer | Sale at price 24.25 - 24.26 per share. | 9.3K | $224.45K |
| Sep 7, 2026 | Foehr DavidOfficer | Conversion of Exercise of derivative security at price 4.70 per share. | 7.5K | $35.25K |
| Sep 1, 2026 | Chao XingjuanChief Executive Officer | Sale at price 24.61 per share. | 39.5K | $973.08K |
| Sep 1, 2026 | Chao XingjuanChief Executive Officer | Conversion of Exercise of derivative security at price 4.70 per share. | 25K | $117.50K |
| Sep 1, 2026 | Blumberg ScottChief Financial Officer | Sale at price 25.00 per share. | 652 | $16.30K |
| Sep 1, 2026 | Blumberg ScottChief Financial Officer | Conversion of Exercise of derivative security at price 9.41 per share. | 652 | $6.13K |
| Aug 23, 2026 | Foehr DavidOfficer | Sale at price 23.95 - 24.02 per share. | 1.9K | $44.42K |
| Aug 20, 2026 | Chao XingjuanChief Executive Officer | Sale at price 24.02 per share. | 6.1K | $145.75K |
| Aug 20, 2026 | Woo RaymondChief Technology Officer | Sale at price 24.02 per share. | 2K | $47.54K |
| Aug 20, 2026 | Blumberg ScottChief Financial Officer | Sale at price 24.02 per share. | 1.5K | $36.53K |
| Aug 20, 2026 | Manni Joseph SOfficer | Sale at price 24.02 per share. | 1.4K | $32.69K |
| Aug 18, 2026 | Chao XingjuanChief Executive Officer | Sale at price 25.00 - 25.03 per share. | 33.6K | $841.29K |
| Aug 18, 2026 | Blumberg ScottChief Financial Officer | Sale at price 25.00 - 25.03 per share. | 34.5K | $863.55K |
| Aug 18, 2026 | Blumberg ScottChief Financial Officer | Conversion of Exercise of derivative security at price 4.70 - 9.41 per share. | 34.5K | $292.31K |
| Aug 12, 2026 | Chao XingjuanChief Executive Officer | Conversion of Exercise of derivative security at price 2.24 - 3.65 per share. | 33.1K | $109.39K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.0 | -9.4 | -1.8 | 10.0 | -8.5 | 5.4 | -9.0 | 35.6 | 1.7 | 7.2 | +19.2% | ||
| 2025 | -11.1 | 1.0 | -17.3 | -16.2 | 4.5 | 11.4 | -23.1 | -17.8 | -2.9 | -0.8 | 48.9 | 29.2 | −15.3% |
| 2024 | 9.5 | -10.1 | −1.6% |
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Buy / hold / sell counts